FINWIRES · TerminalLIVE
FINWIRES

HKG:3320

5 stories mentioning HKG:3320Updated 14d ago

Every FINWIRES story that references HKG:3320, newest first.

Asia

China Resources Pharma Unit Gets China Acceptance for 5 Billion Yuan Bond Issue; Shares Climb 3%

A unit of China Resources Pharmaceutical Group (HKG:3320) obtained a registration acceptance notice for the proposed issue of medium-term bonds from the National Association of Financial Market Institutional Investors, according to a May 29 Hong Kong bourse filing.Shares of the pharmaceutical firm were up over 2% in Monday afternoon trading.The acceptance will allow unit China Resources Pharmaceutical Holdings to issue up to 5 billion yuan of bonds in various tranches within two years.Proceeds from the issue are expected to be used to replenish working capital and repay debt among other uses.

HKG:3320
Asia

China Resources Pharmaceutical Unit Sells 1.4 Billion Yuan Bonds

China Resources Pharmaceutical (HKG:3320) unit China Resources Pharmaceutical Commercial Group completed the issue of 1.4 billion yuan of 1.65% corporate bonds in China maturing in three years, according to a Tuesday Hong Kong bourse filing.The pharma firm intends to use proceeds for production expenditures, including the replenishment of working capital, repayment of debt, and project investments.

HKG:3320
Asia

Dong-E-E-Jiao's Profit Jumps 7% in Q1, Revenue Up 5.5%

Dong-E-E-Jiao (SHE:000423) posted net profit of 454.8 million yuan for the first quarter of 2026, up 7% from 424.6 million yuan a year earlier, according to a Shenzhen bourse filing over the weekend.Earnings per share edged up to 0.7080 yuan from 0.6615 yuan.Revenue rose 5.5% to 1.81 billion yuan from 1.72 billion yuan in the prior-year period.The donkey-hide gelatin producer is a unit of China Resources Pharmaceutical (HKG:3320).

HKG:3320SHE:000423
Asia

CR Double-Crane's Profit, Revenue Fall in Q1

China Resources Double-Crane Pharmaceutical (SHA:600062) posted net profit of 501.4 million yuan for the first quarter of 2026, down from 522.7 million yuan a year earlier, according to an April 24 Hong Kong bourse filing by parent China Resources Pharmaceutical (HKG:3320).Revenue fell to 2.81 billion yuan from 3.08 billion yuan in the prior year period.

HKG:3320SHA:600062
Asia

China Resources Pharma Unit Sells 1.5 Billion Yuan Bonds

China Resources Pharmaceutical (HKG:3320) unit China Resources Pharmaceutical Holdings completed the issue of 1.5 billion yuan of corporate bonds to qualified investors in China, according to a Thursday Hong Kong bourse filing.The bonds carry a coupon rate of 1.65% per annum and will fall due in three years.The unit will use proceeds for corporate debt repayment, working capital replenishment, project development and operation expenditures, certain investments, and other purposes.

HKG:3320

Track with the FINWIRES app suite

FolioX
Track HKG:3320 in your portfolio
WheelAI
Analyze HKG:3320 options with the wheel strategy
StockInsider
See market sentiment on HKG:3320